FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

moduce	uon ±(b).			Filec		on 30(h) of the						<del></del>						
1. Name and Address of Reporting Person* <u>Kieffer Tara Lynn</u>				2. Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC [ ENTA ]						(Che	5. Relationship of Reporting Person(s) to Issi (Check all applicable)  Director 10% Ow  Officer (give title Other (s							
	(Last) (First) (Middle) C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET				3. Date of Earliest Transaction (Month/Day/Year) 11/19/2021							Sr. VP, New Product Dev.						
(Street) WATERTOWN MA 02472				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				1			
(City) (State) (Zip)					ative Securities Acquired, Disposed of, or Benefic								isially Comed					
1. Title of Security (Instr. 3)  2. Transa Date				action Day/Year)	3. 4. Sec			rities	Acquired (D) (Instr.	(A) or	) or 5. Amount Securities Beneficiall Owned Fol		6. Owners Form: Dir (D) or Ind (I) (Instr.	ect (irect I	7. Nature of Indirect Beneficial Ownership			
							Cod	e V	Amoun	t	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)	
Common Stock 1				11/19	/2021		A <sup>(1</sup>		6,80	00	0 A		6,	6,800				
		-				urities Acqı s, warrants							Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day	ate, Ti	ransaction ode (Instr.	5. Number of Derivative Securities	Expirat	Exercisable and tion Date of Securities Underlying Derivative Securities		3	Derivative derivative Security Security		Ow For	nership	11. Nature of Indirect Beneficial Ownership			

## 11/19/2021 \$75.33 (right to buy)

Stock Option Derivative Security

**Explanation of Responses:** 1. Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

Date

Exercisable

(D)

Expiration

11/19/2031

Acquired (A) or Disposed

of (D) (Instr. 3, 4 and 5)

(A)

28,400

/s/ Nathaniel S. Gardiner as

11/23/2021

Owned Following

Reported

Transaction(s) (Instr. 4)

28,400

or Indirect (I) (Instr. 4)

attorney-in-fact

(Instr. 3 and 4)

Title

Stock

Amount or Number

Shares

28,400

\$<mark>0</mark>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).